CA
NZ
UK
AU
IND
US
…
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -19.85M | -29.90M | -39.24M | -24.32M | -8.52M |
| Net income | -19.86M | -29.92M | -39.26M | -24.34M | -8.52M |
| Selling general administrative | 8.49M | 7.89M | 8.08M | 5.36M | 5.25M |
| Reconciled depreciation | - | - | - | - | 0.00M |
| Ebit | - | -60.68M | -78.71M | -24.31M | -10.10M |
| Ebitda | -19.83M | -29.88M | -39.21M | -24.11M | -10.10M |
| Depreciation and amortization | - | 30.80M | 39.50M | 0.19M | 1.59M |
| Operating income | -20.20M | -30.80M | -39.50M | -24.31M | -10.10M |
| Other operating expenses | 20.20M | 30.80M | 39.50M | 24.31M | 10.10M |
| Interest expense | 0.01M | 0.02M | 0.03M | 0.18M | 0.00M |
| Tax provision | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M |
| Interest income | 0.31M | 0.36M | 0.50M | 0.18M | - |
| Net interest income | 0.30M | 0.34M | 0.50M | 0.18M | -0.00M |
| Income tax expense | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 20.20M | 30.80M | 39.50M | 24.31M | 10.10M |
| Total other income expense net | 0.35M | 0.90M | 0.26M | -0.01M | 1.59M |
| Net income from continuing ops | -19.86M | -29.92M | -39.26M | -24.34M | -8.52M |
| Net income applicable to common shares | - | - | - | -24.34M | -8.52M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 15.92M | 15.50M | 23.70M | 18.92M | 31.40M |
| Other current assets | 0.66M | 1.21M | 0.33M | 0.40M | 1.72M |
| Total liab | 7.28M | 14.69M | 17.98M | 6.61M | 2.72M |
| Total stockholder equity | 8.65M | 0.81M | 5.72M | 12.32M | 28.69M |
| Other current liab | 3.86M | 7.86M | - | 2.52M | 1.84M |
| Common stock | 0.01M | 0.00M | - | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -184.14M | -164.27M | -134.35M | -91.17M | -66.83M |
| Other liab | - | - | - | 0.57M | 0.37M |
| Other assets | - | - | - | 0.40M | 1.72M |
| Cash | 14.44M | 13.48M | 23.37M | 18.52M | 29.69M |
| Total current liabilities | 7.28M | 14.60M | 17.18M | 6.04M | 2.34M |
| Net debt | -14.03M | -13.02M | - | -18.52M | -29.69M |
| Short term debt | 0.41M | 0.46M | - | - | - |
| Short long term debt | 0.41M | 0.46M | - | - | - |
| Short long term debt total | 0.41M | 0.46M | - | - | - |
| Other stockholder equity | 192.77M | 165.08M | - | 103.49M | 95.52M |
| Total current assets | 15.10M | 14.68M | 23.70M | 18.92M | 31.40M |
| Net tangible assets | - | - | - | 12.32M | 28.69M |
| Accounts payable | 3.01M | 6.28M | 3.85M | 3.52M | 0.51M |
| Non currrent assets other | 0.82M | 0.82M | - | - | - |
| Non current assets total | 0.82M | 0.82M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | 3.01M | -0.50M |
| Net borrowings | -0.05M | 0.46M | 0.00M | - | - |
| Total cash from financing activities | 25.56M | 23.65M | 33.17M | 7.79M | 31.60M |
| Change to operating activities | - | - | - | 2.00M | -0.20M |
| Net income | -19.86M | -29.92M | -39.26M | -24.34M | -8.52M |
| Change in cash | 0.96M | -9.89M | 4.85M | -11.17M | 20.93M |
| Begin period cash flow | 13.48M | 23.37M | 18.52M | 29.69M | 8.76M |
| End period cash flow | 14.44M | 13.48M | 23.37M | 18.52M | 29.69M |
| Total cash from operating activities | -24.59M | -33.54M | -28.32M | -18.96M | -10.67M |
| Issuance of capital stock | 18.63M | 23.19M | 27.49M | 7.77M | 31.50M |
| Depreciation | - | - | - | - | 0.00M |
| Other cashflows from financing activities | 25557078.44M | 0.00M | 5.68M | 0.02M | 0.10M |
| Change to netincome | - | - | - | 0.37M | -1.44M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -6.87M | -4.54M | 7.28M | 5.01M | -0.70M |
| Stock based compensation | 2.23M | 1.63M | 3.41M | 0.18M | 0.11M |
| Other non cash items | -0.09M | -0.72M | 0.24M | 0.19M | -1.55M |
| Free cash flow | -24.59M | -33.54M | -28.32M | -18.96M | -10.67M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RVPH Reviva Pharmaceuticals Holdings Inc. |
- -% |
0.34 | - | - | - | 0.41 | -6.00 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
10080 N. Wolfe Road, Cupertino, CA, United States, 95014
408 501 8881
14
| Name | Title | Year Born |
|---|---|---|
| Dr. Laxminarayan Bhat Ph.D. | Founder, CEO, Pres & Director | 1965 |
| Mr. Narayan Prabhu | Chief Financial Officer | 1972 |
| Dr. Laxminarayan Bhat Ph.D. | Founder, CEO, President & Director | 1965 |
| Dr. Laxminarayan Bhat Ph.D. | Founder, CEO, President & Director | 1966 |
| Mr. Narayan Prabhu | CFO, Treasurer & Secretary | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...